CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (age 12 years and above) who are candidates for systemic therapy and whose disease is not adequately controlled with topical medications or for whom topical treatments are otherwise medically inadvisable.